Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucoma

Clinical Drug Investigation

Volumn 32, Issue 12, 2012, Pages 835-842

  Schmier, Jordana K ^a   Covert, David W ^b   Lau, Edmund C ^a  

^a EXPONENT INC   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIMOLOL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DATA BASE; FEMALE; GLAUCOMA; HEALTH CARE COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICAL SERVICE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADMINISTRATION, OPHTHALMIC; ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; FEMALE; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RESPIRATORY TRACT DISEASES; RETROSPECTIVE STUDIES; TIME FACTORS; TIMOLOL;

EID: 84873428953     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-012-0027-z     Document Type: Article

References (30)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-7.
2. Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ. 2008;86(1):63-70.
3. American Academy of Ophthalmology. Preferred practice pattern. In: Primary open-angle glaucoma. Limited revision. San Francisco: American Academy of Ophthalmology; 2003.
4. Duggal P, Klein AP, Lee KE, Iyengar SK, Klein R, Bailey-Wilson JE, et al. A genetic contribution to intraocular pressure: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 2005;46(2):555-60.
5. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(2):205-9.
6. Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology. 2007;114(1):3-9.
7. Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology. 2005;112(3):376-85.
8. IMS Global Track 2009.
9. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-13 (discussion 829-30).
10. American Academy of Ophthalmology. Preferred practice pattern. In: Primary open angle glaucoma. San Francisco: American Academy of Ophthalmology; 2010.
11. American Optometric Association. Optometric clinical practice guideline. In: Care of the patient with open angle glaucoma. St. Louis: American Optometric Association; 2010.
12. National Institute for Health and Clinical Excellence. Glaucoma. In: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. London: National Institute for Health and Clinical Excellence; 2009.
13. Houde M, Castilloux AM, Tingey D, Assalian A, LeLorier J. Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers. Can J Ophthalmol. 2003;38(6):469-75.
14. Vinker S, Kaiserman I, Waitman DA, Blackman S, Kitai E. Prescription of ocular beta-blockers in patients with obstructive pulmonary disease: does a central electronic medical record make a difference? Clin Drug Investig. 2006;26(9):495-500.
15. Valuck RJ, Perlman JI, Anderson C, Wortman GI. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers. Pharmacoepidemiol Drug Saf. 2001;10(6):511-6.
16. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf. 2005;28(1):67-80.
17. MAG Mutual Healthcare Solutions I. ICD-9-CM Volumes 1 & 2 for Physicians' Expert Edition. Atlanta: MAG Mutual Healthcare Solutions, Inc.; 2012.
18. Kaiserman I, Fendyur A, Vinker S. Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res. 2009;34(7):517-22.
19. Frishman WH, Kowalski M, Nagnur S, Warshafsky S, Sica D. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade. Heart Dis. 2001;3(6):386-97.
20. Han JA, Frishman WH, Wu Sun S, Palmiero PM, Petrillo R. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev. 2008;16(2):95-108.
21. Diggory P, Cassels-Brown A, Fernandez C. Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people. Age Ageing. 1996;25(6):424-8.
22. Diggory P, Heyworth P, Chau G, McKenzie S, Sharma A. Unsuspected bronchospasm in association with topical timolol - a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? Age Ageing. 1994;23(1):17-21.
23. Diggory P, Heyworth P, Chau G, McKenzie S, Sharma A, Luke I. Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. Eye (Lond). 1993;7(Pt 5):661-3.
24. Gandolfi SA, Chetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial reactivity in healthy individuals undergoing long-term topical treatment with beta-blockers. Arch Ophthalmol. 2005;123(1):35-8.
25. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113(7):1069-76.
26. Ramdas WD, van der Velde N, van der Cammen TJ, Wolfs RC. Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users. Graefes Arch Clin Exp Ophthalmol. 2009;247(9):1235-41.
27. Uusitalo H, Kahonen M, Ropo A, Maenpaa J, Bjarnhall G, Hedenstrom H, et al. Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol. 2006;244(11):1491-6.
28. Gray CL, Gardner C. Adverse drug events in the elderly: an ongoing problem. J Manag Care Pharm. 2009;15(7):568-71.
29. Cresswell KM, Fernando B, McKinstry B, Sheikh A. Adverse drug events in the elderly. Br Med Bull. 2007;83:259-74.
30. Murakami Y, Lee BW, Duncan M, Kao A, Huang JY, Singh K, et al. Racial and ethnic disparities in adherence to glaucoma follow-up visits in a county hospital population. Arch Ophthalmol. 2011;129(7):872-8.